Recap: Onconova Therapeutics Q2 Earnings

Shares of Onconova Therapeutics ONTX moved higher by 2.1% in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share fell 575.00% over the past year to ($0.27), which beat the estimate of ($0.28).

Revenue of $57,000 higher by 1.79% year over year, which beat the estimate of $20,000.

Guidance

Onconova Therapeutics hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Aug 12, 2021

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/pa52h9au

Technicals

Company's 52-week high was at $10.84

Company's 52-week low was at $0.19

Price action over last quarter: down 67.28%

Company Description

Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!